Aptamers: an innovative therapeutic approach to septic coagulopathy.

Maeva Martin, first author—under the supervision of Laurence Choulier - and co-directed by Julie Helms -  along with Marine Tschirhart, Cyril Auger, and Florence Toti from the  UMR 1260 Regenerative Nanomedicine unit (University of Strasbourg/Inserm), present a new review published in Annals of Intensive Care (Elsevier). This review highlights the potential of aptamers as diagnostic and prognostic tools.

Sepsis-induced coagulopathy remains a major therapeutic challenge, associated with high mortality and severe organ dysfunction. An alternative therapeutic option is emerging with aptamers—synthetic oligonucleotides with unique properties: high specificity and affinity, low immunogenicity, and synthetic production.

The authors demonstrated the therapeutic flexibility of aptamers in targeting multiple key mechanisms, including:

  • Endothelial protection,
  • Coagulation regulation,
  • And restoration of fibrinolysis.

A promising breakthrough!

The authors acknowledge the support of Adiral Assistance and FHUTARGET.

Congratulations to the authors for this fruitful collaboration!

 

Link: https://doi.org/10.1016/j.aicoj.2025.100014